AVIR Atea Pharmaceuticals, Inc.

NASDAQ
$5.17

Atea Pharmaceuticals, Inc. (AVIR) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.50 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -0.8% since its last earnings release on August 12, 2026.

Atea Pharmaceuticals Beat Consensus Estimates
Wednesday, August 12, 2026 · 4:05 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.50)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $5.36

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.